Dr Reddy’s Laboratories Ltd has launched Pramipexole dihydrochloride extended-release tablets in the US market.
The drug is a therapeutic equivalent generic version of Mirapex ER (pramipexole dihydrochloride) extended-release tablets. It is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG Corporation. It is indicated in the treatment of Parkinson’s.
The Mirapex ER brand and generic had U.S. sales of approximately $48.3 million for the most recent twelve months ending in June 2015 according to IMS Health.
Dr Reddy’s scrip gained 1.08 per cent on the Bombay Stock Exchange on Wednesday to end at Rs 4,276.70.